Objective: Clinicians have access to a variety of formulations of methylphenidate and amphetamine to treat attention-deficit hyperactivity disorder (ADHD). However, due to new emerging formulations cl..
Objective: Clinicians have access to a variety of formulations of methylphenidate and amphetamine to treat attention-deficit hyperactivity disorder (ADHD). However, due to new emerging formulations clinicians may lack up-to-date knowledge about all available stimulant formulations. We present a comprehensive guide of 13 formulations of methylphenidate and 10 formulations of amphetamine that have U.S. Food and Drug Administration (FDA) approval to treat ADHD. Methods: A systematic review was completed through PUBMED using the following MeSH terms: “attention-deficit hyperactivity disorder”, “ADHD”, “stimulant”, “amphetamine”, and “methylphenidate”. Conclusions: Each formulation has a unique pharmacokinetic profile. Clinically, one formulation may not be suitable for all patients. This review should provide clinical guidance to help clinicians prescribe the most suitable treatment for an individual.